INNOVIVA INC (INVA)
US45781M1018 - Common Stock
Innoviva Specialty Therapeutics’ Positive Phase 3 Oral Zoliflodacin Data for the Treatment of Uncomplicated Gonorrhea Announced at ESCMID Global 2024
Oversold Conditions For Innoviva (INVA)
Armata Pharmaceuticals Announces $35 Million Secured Credit Agreement with Innoviva
/PRNewswire/ -- Armata Pharmaceuticals, Inc. (NYSE American: ARMP) ("Armata" or the "Company"), a biotechnology company focused on pathogen-specific...
Innoviva Reports Fourth Quarter and Full Year 2023 Financial Results; Highlights Recent Company Progress
Interesting INVA Put And Call Options For September 20th
If You Can Only Buy One Biotech Stock in January, It Better Be One of These 3 Names
Biotech is one of the areas of interest in the market today, adding a biotech stock could be huge play this month.
Innoviva Reports Third Quarter 2023 Financial Results and Highlights Recent Company Progress
Positive Results Announced in Largest Pivotal Phase 3 Trial of a First-in-Class Oral Antibiotic to Treat Uncomplicated Gonorrhea
Innoviva Breaks Below 200-Day Moving Average - Notable for INVA
Innoviva to Participate in the Cantor Global Healthcare Conference
Innoviva names Stephen Basso as finance chief (NASDAQ:INVA)
Innoviva (INVA) said on Friday that it had appointed Stephen Basso as chief financial officer, effective August 21.More recently, Basso served as the CFO and chief operating officer...
Innoviva Appoints Stephen Basso as Chief Financial Officer
Innoviva Reports Second Quarter 2023 Financial Results and Highlights Recent Company Progress
SHAREHOLDER ALERT: Purcell & Lefkowitz LLP Is Investigating Innoviva, Inc. for Potential Breaches of Fiduciary Duty By Its Board of Directors
/PRNewswire/ -- Purcell & Lefkowitz LLP, a class action law firm dedicated to representing shareholders nationwide, is investigating a potential breach of...
Why These 7 Stocks Are the Best Ways to Play Biotech Right Now
With biotech stocks offering myriad viable opportunities irrespective of broader conditions, this sector is worth a closer look.
Armata Pharmaceuticals gets $25M in financing and new executive chief (NYSE:ARMP)
Biotechnology company focused on pathogen‐specific bacteriophage therapeutics for antibiotic‐resistant and difficult‐to‐treat bacterial infections, Armata Pharmaceuticals (ARMP) enters...
Armata Pharmaceuticals Announces New Financing and Leadership Transition to Accelerate Novel Bacteriophage Therapeutics
/PRNewswire/ -- Armata Pharmaceuticals, Inc. (NYSE American: ARMP) ("Armata" or the "Company"), a biotechnology company focused on pathogen‐specific...
Innoviva to Participate in the Goldman Sachs Annual Global Healthcare Conference
Wednesday 5/31 Insider Buying Report: INVA, DRVN
(NASDAQ:INVA)
Innoviva press release (INVA): Q1 GAAP EPS of $0.51.Revenue of $76.37M (-15.2% Y/Y).Cash and cash equivalents totaled $144.0 million
Innoviva Reports First Quarter 2023 Financial Results and Highlights Recent Company Progress
Innoviva chairman Bickerstaff to step down after annual meeting (NASDAQ:INVA)
Innoviva (INVA) announced on Friday that chairman George Bickerstaff, III, would not stand for reelection at the company’s 2023 Annual Meeting.After the meeting, assuming that all...
Innoviva Announces Retirement of Board Chairman
Sulbactam-Durlobactam Unanimously Recommended for Approval by FDA Advisory Committee
